Skip to main content
editor@ajptr.com
9409046853
e-ISSN: 2249-3387
American Journal of PharmTech Research

American Journal of PharmTech Research

LoginTrack Your Paper
Published

FORMULATION, OPTIMIZATION AND CHARACTERIZATION OF ORNIDAZOLE NANOSTRUCTURED LIPID CARRIER GEL FOR TOPICAL DELIVERY

, ,

Published in October 2026 Issue 5 (Vol. 16, Issue 5, 2026)

FORMULATION, OPTIMIZATION AND CHARACTERIZATION OF ORNIDAZOLE NANOSTRUCTURED LIPID CARRIER GEL FOR TOPICAL DELIVERY - Issue cover

Keywords

Ornidazolenanostructured lipid carrierstopical gelglyceryl monostearateoleic acidTween 80Box–Behnken designsustained release.

Abstract

The study aimed to formulate, optimize and characterize ornidazole NLCs using glyceryl monostearate (GMS), oleic acid and Tween 80 and to incorporate the optimized dispersion into a topical gel. NLCs were prepared by hot homogenization followed by ultrasonication. A three-factor, three-level Box–Behnken design comprising 17 runs was used to investigate GMS concentration, Tween 80 concentration and homogenization time. Particle size, polydispersity index (PDI), zeta potential, entrapment efficiency, drug content and in vitro drug release were evaluated. FTIR and SEM were used for physicochemical and morphological characterization. The NLC dispersion was incorporated into a Carbopol 934-based gel and evaluated for pH, spreadability, viscosity and stability. The optimized formulation (F13) had a particle size of 222.8 nm, PDI 0.289, zeta potential −26.7 mV, entrapment efficiency 83.6% and drug content 91.0%. The optimized formulation showed sustained drug release, with 82.3% cumulative drug release reported at 12 h in the response-optimization section. The optimized gel showed pH 5.73 ± 0.03, spreadability 6.28 ± 0.21 g·cm/s and viscosity 5080 ± 78 cP. FTIR analysis showed retention of characteristic ornidazole peaks without major drug–excipient interaction. The optimized formulation remained physically stable during the reported 60-day study. The study demonstrates the feasibility of developing an ornidazole-loaded NLC topical gel using a Box–Behnken design. The optimized formulation exhibited nanoscale particle size, acceptable PDI, measurable negative zeta potential, good entrapment and sustained drug release, supporting further investigation as a topical delivery system.

References

  1. [1]Harde H, Das M, Jain S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin Drug Deliv. 2011;8:1407–1424.
  2. [2]Jahanshahi M, Babaei Z. Protein nanoparticle: a unique system for drug delivery vehicles. Afr J Biotechnol. 2008;7.
  3. [3]Müller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev. 2007;59:522–530.
  4. [4]Selvamuthukumar S, Velmurugan R. Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lipids Health Dis. 2012;11:159.
  5. [5]Patel DK, Tripathy S, Nair SK, Kesharwani R. Nanostructured lipid carrier (NLC): a modern approach for topical delivery – a review. World J Pharm Pharm Sci. 2013;2(3):921–938.
  6. [6]McPherson ML, Cimino NM. Topical NSAID formulations. Pain Med. 2013;14:S35–S39.
  7. [7]Kalra MG, Higgins KE, Kinney BS. Intertrigo and secondary skin infections. Am Fam Physician. 2014;89(7):569–573.
  8. [8]Hoang MP, Ogawa T, Marques MEA. Infection: Bacteria, Spirochetes, Protozoa, and Infestation. In: Hoang M, Selim M, editors. Hospital-Based Dermatopathology. Cham: Springer; 2020.
  9. [9]Goldsmid JM, Melrose W. Parasitic infections of the skin. In: Primer of Tropical Medicine. Australasian College of Tropical Medicine; 2005.
  10. [10]Lupi O, Bartlett BL, Haugen RN, Dy LC, Sethi A, Klaus SN, Machado Pinto J, Bravo F, Tyring SK. Tropical dermatology: Tropical diseases caused by protozoa. J Am Acad Dermatol. 2009;60(6):897–925.
  11. [11]Bhutani H, Kurmi M, Singh S, Beg S, Singh B. Quality by Design (QbD) in analytical sciences: an overview. Quality Assurance. 2004;3:39–45.
  12. [12]Box GE, Wilson KB. On the experimental attainment of optimum conditions. J R Stat Soc Series B. 1951;13:1–45.
  13. [13]Shukla V, Vasudha M, Bhardwaj V, Masareddy RS, Manvi FV. Preparation and evaluation of periodontal gel of ornidazole using natural polymers. Der Pharm Lett. 2010;2(1):61–69.
  14. [14]Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: a novel drug targeting carrier. J Drug Deliv Sci Technol. 2019;51:255–267.
  15. [15]Thapa C, Ahad A, Aqil M, Imam SS, Sultana Y. Formulation and optimization of nanostructured lipid carriers to enhance oral bioavailability of telmisartan using Box–Behnken design. J Drug Deliv Sci Technol. 2018;44:431–439.
  16. [16]Patwekar SL, Pedewad SR, Gattani S. Development and evaluation of nanostructured lipid carriers-based gel of isotretinoin. Particulate Sci Technol. 2018;36(7):832–843.
  17. [17]Chen YC, Liu DZ, Liu JJ, Chang TW, Ho HO, Sheu MT. Development of terbinafine solid lipid nanoparticles as a topical delivery system. Int J Nanomed. 2012;7:4409–4418.
  18. [18]Pimentel-Moral S, Teixeira MC, Fernandes AR, Borrás-Linares I, Arráez-Román D, Martínez-Férez A, Segura-Carretero A, Souto EB. Polyphenols-enriched Hibiscus sabdariffa extract-loaded nanostructured lipid carriers: optimization by multi-response surface methodology. J Drug Deliv Sci Technol. 2019;49:660–667.
  19. [19]Zhang X, Liu J, Qiao H, Liu H, Ni J, Zhang W, Shi Y. Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol. 2010;197:120–128.
  20. [20]Mahdi WA, Bukhari SI, Imam SS, Alshehri S, Zafar A, Yasir M. Formulation and optimization of butenafine-loaded topical nano lipid carrier-based gel: characterization, irritation study, and anti-fungal activity. Pharmaceutics. 2021;13(7):1087.
  21. [21]Ferreira M, Chaves LL, Lima SA, Reis S. Optimization of nanostructured lipid carriers loaded with methotrexate: a tool for inflammatory and cancer therapy. Int J Pharm. 2015;492:65–72.
  22. [22]Pawbake GR, Shirolkar SV. Formulation, development and evaluation of nanostructured lipid carrier (NLC) based gel for topical delivery of diacerein. Syst Rev Pharm. 2020;11(6):794–802.
  23. [23]Han F, Yin R, Che X, Yuan J, Cui Y, Yin H, Li S. Nanostructured lipid carriers (NLC) based topical gel of flurbiprofen: design, characterization and in vivo evaluation. Int J Pharm. 2012;439:349–357.
  24. [24]Rajesh P, Gunasekaran S, Gnanasambandan T, Seshadri S. Experimental and theoretical study of ornidazole. Spectrochim Acta A Mol Biomol Spectrosc. 2016;153:496–504.

Authors (3)

P. Ashok Kumar

Department of Pharmaceutics, S...

View all publications →

Kavya TS

Department of Pharmaceutics, S...

View all publications →

Suresh V. Kulkarni

Department of Pharmaceutics, S...

View all publications →

Download Article

PDF

Best for printing and citation

File size: 1.5 MB
Format: PDF
ViewDownload

Summarise this paper with AI:

GoogleGooglePerplexityPerplexityGrokGrokChatGPTChatGPTClaudeClaude

Article Information

Published in:

October 2026 Issue 5 (Vol. 16, Issue 5, 2026)

AJPTR5160013

AJPTR-02-002520

191-209

2026-11-02

JATS XML

Article Impact

Views:2,258
Downloads:2,126

How to Cite

Ashok Kumar, P., TS, K., & Kulkarni, S. V. (2026). FORMULATION, OPTIMIZATION AND CHARACTERIZATION OF ORNIDAZOLE NANOSTRUCTURED LIPID CARRIER GEL FOR TOPICAL DELIVERY. American Journal of PharmTech Research, 16(5), 191-209. https://ajptr.com/articles/AJPTR5160013

Article Actions

Whatsapp